Biohaven's depression drug fails mid-stage trial, shares fall [Yahoo! Finance]
Biohaven Pharmaceutical Holding Company Ltd. Common Shares (BHVN)
Last biohaven pharmaceutical holding company ltd. common shares earnings: 2/25 04:45 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.biohavenpharma.com
Company Research
Source: Yahoo! Finance
trial, adding to a string of trial and regulatory ?setbacks for the drugmaker this year. The company's shares fell 17% in extended trading and are ?down more than 70% this year, weighed down by a clinical trial failure in March and the U.S. health regulator's rejection of its drug troriluzole for a rare neurodegenerative disorder. Biohaven's drug, BHV-7000, when tested in patients with ?major depressive disorder in a ?six-week trial did not show significant reduction in depressive symptoms compared with placebo as measured by change in the ?Montgomery Asberg Depression Rating Scale. The company considers the depression subgroup analyses as "hypothesis generating" but does not plan on additional psychiatric clinical trials to keep resources focused on ?key priority areas of immunology, obesity and epilepsy in 2026. RBC Capital ?Markets analyst Leonid Timashev said the trial miss is "not surprising" given the limited clinical efficacy data to date and MDD being a challenging ind
Show less
Read more
Impact Snapshot
Event Time:
BHVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BHVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BHVN alerts
High impacting Biohaven Pharmaceutical Holding Company Ltd. Common Shares news events
Weekly update
A roundup of the hottest topics
BHVN
News
- Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder [Yahoo! Finance]Yahoo! Finance
- Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive DisorderPR Newswire
- Biohaven (BHVN): Valuation Check After Encouraging BHV-1510 Immuno-Oncology Data at ESMO Congress [Yahoo! Finance]Yahoo! Finance
- Biohaven (BHVN) Is Down 5.9% After New BHV-1510 Combo Data - What's Changed [Yahoo! Finance]Yahoo! Finance
- Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress [Yahoo! Finance]Yahoo! Finance
BHVN
Earnings
- 11/10/25 - Beat
BHVN
Sec Filings
- 11/18/25 - Form 4
- 11/17/25 - Form 4
- 11/17/25 - Form 4
- BHVN's page on the SEC website